Difference between revisions of "Team:UiOslo Norway"
Markushovd (Talk | contribs) |
Markushovd (Talk | contribs) |
||
| Line 31: | Line 31: | ||
<p style="text-align:justify;"> During their lifetime 75% of women will experience a <em>Candida albicans</em> infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by <em>C. albicans</em>. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult. | <p style="text-align:justify;"> During their lifetime 75% of women will experience a <em>Candida albicans</em> infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by <em>C. albicans</em>. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult. | ||
</p> | </p> | ||
| − | <p>Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for <em>C. albicans</em> infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on <em>C. albicans</em> specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of <em>C. albicans</em> DNA. | + | <p style="text-align:justify;">Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for <em>C. albicans</em> infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on <em>C. albicans</em> specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of <em>C. albicans</em> DNA. |
</p> | </p> | ||
</div> | </div> | ||
Revision as of 15:17, 2 November 2018
Fast detection of vulvovaginal Candida albicans infections using CRISPR/dCas9
UiOslo_Norway
Awarded Best Diagnostic ProjectNominated Best Presentation
During their lifetime 75% of women will experience a Candida albicans infection, one of the most common vulvovaginal yeast infections. Currently there are no fast methods to detect whether an infection is caused by C. albicans. As a result, women purchase over-the-counter antimycotics without knowing the cause of their infection. This contributes to the rise of antimycotic resistance, making treatment of future infections more difficult.
Based on previous projects, UiOslo_Norway aims to develop a fast detection kit for C. albicans infections, using CRISPR/dCas9. Upon a suspected infection, a vaginal sample will be treated with glucanase to selectively lyse yeast cells walls, exposing the fungal DNA. Afterwards, modified dCas9 enzymes fused with split β-lactamase are added. Using specifically designed guideRNAs, the dCas9 complexes bind adjacently on C. albicans specific DNA sequences. This activates the β-lactamase to cleave its substrate nitrocefin, producing a colored product indicating the presence of C. albicans DNA.